GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (XSWX:ROG) » Definitions » Total Inventories

Roche Holding AG (XSWX:ROG) Total Inventories : CHF7,749 Mil (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Roche Holding AG Total Inventories?

Roche Holding AG's total inventories for the quarter that ended in Dec. 2023 was CHF7,749 Mil. Roche Holding AG's average total inventories from the quarter that ended in Jun. 2023 to the quarter that ended in Dec. 2023 was CHF8,123 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Roche Holding AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was CHF-47.72.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Roche Holding AG's Days Inventory for the six months ended in Dec. 2023 was 175.93.

Inventory Turnover measures how fast the company turns over its inventory within a year. Roche Holding AG's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.04.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Roche Holding AG's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.27.


Roche Holding AG Total Inventories Historical Data

The historical data trend for Roche Holding AG's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Total Inventories Chart

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,055.00 7,194.00 7,715.00 8,605.00 7,749.00

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,715.00 8,292.00 8,605.00 8,496.00 7,749.00

Roche Holding AG Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Roche Holding AG  (XSWX:ROG) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Roche Holding AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(10510+0.75 * 11636+0.5 * 7749-57205
-0-3948)/797.242
=-47.72

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Roche Holding AG's Days Inventory for the six months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=8122.5/8426*365 / 2
=175.93

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Roche Holding AG's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=8426 / 8122.5
=1.04

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Roche Holding AG's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=8122.5 / 29825
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Roche Holding AG Total Inventories Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (XSWX:ROG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.